Episode Details
Back to Episodes
Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml
Published 9 months, 4 weeks ago
Description
The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.